Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.54 |
| ▸ | TDO2 | P48775 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.46 |
| ▸ | CCR2 | P41597 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12628038 | 0.81 | POLB (0.52) | POLBROCK2ROCK1CCR2 | |
| SCHEMBL3536081 | 0.80 | POLB (0.52) | IDO1TDO2POLBROCK2ROCK1 | |
| SCHEMBL5404817 | 0.79 | POLB (0.48) | TDO2POLBROCK2ROCK1CCR2 | |
| SCHEMBL3311306 | 0.77 | PRMT3 (0.44) | IDO1TDO2ROCK1 | |
| SCHEMBL4291558 | 0.76 | PKM (0.39) | IDO1TDO2POLB | |
| SCHEMBL11934772 | 0.75 | ULK1 (0.49) | POLBROCK2ROCK1CCR2 | |
| SCHEMBL5405984 | 0.75 | ROCK2 (0.53) | POLBROCK2ROCK1CCR2 | |
| SCHEMBL13438658 | 0.75 | ULK1 (0.49) | POLBROCK2ROCK1CCR2 | |
| SCHEMBL5418817 | 0.74 | ROCK2 (0.48) | POLBROCK2ROCK1CCR2 | |
| SCHEMBL261563 | 0.72 | ROCK2 (0.50) | ROCK2ROCK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | IDO1 1393/4885TDO2 2427/4885POLB 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.